Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

PHASE2CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

August 5, 2023

Study Completion Date

September 28, 2023

Conditions
Moderate to Severe Persistent Asthma
Interventions
DRUG

CBP-201

CBP-201 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (76)

4150

Connect Investigative Site 304, Püspökladány

9700

Connect Investigative Site 303, Szombathely

10036

Connect Investigative Site 153, New York

11004

Connect Investigative Site 220, Shenyang

13496

Connect Investigative Site 503, Seongnam-si

14010

Connect Investigative Site 214, Baotou

14201

Connect Investigative Site 117, Buffalo

21162

Connect Investigative Site 120, White Marsh

21565

Connect Investigative Site 505, Incheon

27104

Connect Investigative Site 122, Winston-Salem

32789

Connect Investigative Site 123, Winter Park

33012

Connect Investigative Site 161, Hialeah

33014

Connect Investigative Site 165, Miami Gardens

Connect Investigative Site 110, Miami Lakes

33021

Connect Investigative Site 114, Hollywood

33126

Connect Investigative Site 104, Miami

33145

Connect Investigative Site 166, Miami

33155

Connect Investigative Site 118, Miami

Connect Investigative Site 162, Miami

33174

Connect Investigative Site 163, Miami

Connect Investigative Site 164, Miami

33176

Connect Investigative Site 105, Miami

34748

Connect Investigative Site 142, Leesburg

43617

Connect Investigative Site 147, Toledo

45236

Connect Investigative Site 136, Cincinnati

48322

Connect Investigative Site 146, West Bloomfield

63141

Connect Investigative Site 112, St Louis

73034

Connect Investigative Site 107, Edmond

73120

Connect Investigative Site 149, Oklahoma City

75231

Connect Investigative Site 121, Dallas

77450

Connect Investigative Site 150, Katy

78006

Connect Investigative Site 102, Boerne

78759

Connect Investigative Site 119, Bellevue

Connect Investigative Site 116, Austin

79903

Connect Investigative Site 108, El Paso

85704

Connect Investigative Site 154, Tucson

89030

Connect Investigative Site 144, North Las Vegas

92647

Connect Investigative Site 109, Huntington Beach

Connect Investigative Site 143, Huntington Beach

92691

Connect Investigative Site 125, Mission Viejo

93534

Connect Investigative Site 132, Lancaster

95117

Connect Investigative Site 103, San Jose

100029

Connect Investigative Site 201, Beijing

100039

Connect Investigative Site 216, Beijing

100730

Connect Investigative Site 209, Beijing

101100

Connect Investigative Site 215, Beijing

130021

Connect Investigative Site 212, Changchun

200025

Connect Investigative Site 207, Shanghai

200433

Connect Investigative Site 218, Shanghai

214023

Connect Investigative Site 205, Wuxi

225007

Connect Investigative Site 208, Yangzhou

233000

Connect Investigative Site 206, Bengbu

315046

Connect Investigative Site 217, Ningbo

410013

Connect Investigative Site 202, Changsha

430000

Connect Investigative Site 213, Wuhan

471003

Connect Investigative Site 211, Luoyang

510080

Connect Investigative Site 203, Guangzhou

830054

Connect Investigative Site 224, Ürümqi

04401

Connect Investigative Site 124, Bangor

08540

Connect Investigative Site 111, Princeton

02886

Connect Investigative Site 129, Warwick

014000

Connect Investigative Site 204, Baotou

010050

Connect Investigative Site 210, Hohhot

030001

Connect Investigative Site 221, Taiyuan

030032

Connect Investigative Site 222, Taiyuan

30-033

Connect Investigative Site 402, Krakow

31-559

Connect Investigative Site 401, Krakow

59-300

Connect Investigative Site 403, Lubin

53-301

Connect Investigative Site 408, Wroclaw

96-100

Connect Investigative Site 406, Skierniewice

15-010

Connect Investigative Site 404, Bialystok

Connect Investigative Site 405, Bialystok

42-200

Connect Investigative Site 410, Częstochowa

26-110

Connect Investigative Site 407, Skarżysko-Kamienna

03080

Connect Investigative Site 501, Seoul

03722

Connect Investigative Site 502, Seoul

Sponsors
All Listed Sponsors
lead

Connect Biopharm LLC

INDUSTRY